Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Capelle Aan Den Ijssel – page 91

1 543 clinical trials in Capelle Aan Den Ijssel, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Capelle Aan Den Ijssel at a glance
1 543
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 543 trials in Capelle Aan Den Ijssel

Open in trial search

Hormone receptor positive HER2 negative breast cancer+1

Not recruiting

Study on Alpelisib and Fulvestrant for Advanced Breast Cancer in Patients with PIK3CA Mutation and Hormone-Receptor Positive, HER2 Negative Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:BOOG Study Center B.V.

Chronic lymphocytic leukaemia

Not recruiting

Study on Venetoclax, Ibrutinib, and Obinutuzumab for Chronic Lymphocytic Leukemia Patients Not in Complete Remission or with Detectable Bone Marrow Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Eosinophilic oesophagitis

Not recruiting

Study on the Effects of EP-104IAR and Tetracosactide for Adults with Eosinophilic Esophagitis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Tetracosactide
  • Sponsor:Eupraxia Pharmaceuticals Inc.

Malignant melanoma

Not recruiting

Study on Early Discontinuation of Nivolumab and Ipilimumab in Patients with Advanced Melanoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Malignant melanoma

Not recruiting

Study Comparing Naporafenib and Trametinib Combination to Other Therapies for Patients with Previously Treated Unresectable or Metastatic NRAS Mutant Melanoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:Erasca Inc.

Transitional cell carcinoma

Not recruiting

Study of BT8009 Alone or with Pembrolizumab for Patients with Advanced or Metastatic Bladder Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Bicycletx Limited

Hepatitis D+1

Not recruiting

Study on the Effects of VIR-2218 and VIR-3434 for Patients with Chronic Hepatitis D Infection

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Vir Biotechnology Inc.

Food allergy

Not recruiting

Study on Long-term Benefits and Safety of DBV712 for Children with Peanut Allergy

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Sponsor:Dbv Technologies

Kidney transplant rejection

Not recruiting

Study on Imlifidase for Highly Sensitized Patients with End-Stage Chronic Kidney Disease Awaiting Transplant

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Imlifidase
  • Sponsor:Hansa Biopharma AB

Multiple sclerosis

Not recruiting

Study on Personalized Ocrelizumab Dosing for Patients with Relapsing Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:Amsterdam UMC Stichting

Systemic lupus erythematosus+3

Not recruiting

Study on the Effects of Ianalumab in Adults with Rheumatoid Arthritis, Systemic Lupus Erythematosus, or Sjögren’s Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Interstitial lung disease

Not recruiting

Study on BI 1015550 for Improving Lung Function in Patients with Progressive Fibrosing Interstitial Lung Diseases

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Capelle Aan Den Ijssel

What the registry says about research in the country

01 Oncology - Colorectal Studies

Multiple innovative trials focusing on colorectal cancer treatment strategies, including research on liver metastases management and chemotherapy optimization for older patients.

  • Hepatic arterial infusion therapy
  • Dose-adjusted chemotherapy protocols
  • Post-surgical treatment approaches

Advanced research exploring both surgical and medical interventions for improved patient outcomes.

02 Hematology & Breast Cancer

Groundbreaking studies in multiple myeloma treatment protocols and innovative approaches for hormone receptor-positive breast cancer management.

  • Treatment-free interval assessment
  • CDK 4/6 inhibition strategies
  • Endocrine therapy optimization

Focus on developing personalized treatment strategies for better long-term outcomes.

03 Inflammatory & Autoimmune Conditions

Comprehensive research on rheumatoid arthritis management, investigating novel treatment timing and personalized therapeutic approaches.

  • Chronotherapy effectiveness
  • Tailored management protocols
  • Cost-effectiveness analysis

Emphasis on patient-centered outcomes and treatment optimization.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.